Ophthalmology · Lubbock, TX
NPI
1639178999
Since 2005
Specialty
Ophthalmology
Code 207W00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
3611 50th St
Lubbock, TX, 79413
Phone (806) 792-5900
Groups this clinician bills Medicare through
Medicare paid, 2024
$235K
4,052 services
Medicare patients, 2024
926
Average age 78
Drug cost, 2024
$736K
9,580 prescriptions
Company payments, 2025
$1,313
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zuhair M Shihab was code 92012 (ophthalmological e&m), 1,639 times for 846 patients. In total Zuhair M Shihab billed 4,052 services in 22 codes, and Medicare paid $235K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92012 Ophthalmological E&M | Office | 1,639 | 846 | $55.20 | $90K |
| 92083 Vision, Hearing, and Speech Services | Office | 699 | 660 | $39.71 | $28K |
| 92133 Computerized Ophthalmic Imaging | Office | 531 | 523 | $21.42 | $11K |
| 92250 Angiography | Office | 312 | 307 | $26.16 | $8,162 |
| 92014 Ophthalmological E&M | Office | 309 | 301 | $77.81 | $24K |
| 65855 Fluid Flow and Drainage of Eye (Any Method) | Facility | 158 | 100 | $142.09 | $22K |
| 92020 Ophthalmological E&M | Office | 139 | 135 | $18.17 | $2,526 |
| 76514 Ultrasound - Nonspecific | Office | 88 | 88 | $6.67 | $587 |
| 92004 Ophthalmological E&M | Office | 58 | 58 | $82.15 | $4,765 |
| 66761 Fluid Flow and Drainage of Eye (Any Method) | Facility | 38 | 20 | $169.29 | $6,433 |
| 66170 Fluid Flow and Drainage of Eye (Any Method) | Facility | 29 | 25 | $768.56 | $22K |
| 92002 Ophthalmological E&M | Office | 22 | 22 | $48.65 | $1,070 |
By year: 2022 $243K for 3,917 services; 2023 $221K for 3,711 services; 2024 $235K for 4,052 services.
Medicare prescription drug claims, 2024
In 2024, the drug Zuhair M Shihab prescribed most often to Medicare patients was Latanoprost, with 3,165 prescriptions and refills. In total Zuhair M Shihab wrote 9,580 Medicare prescriptions that cost $736K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 3,165 | 7,628 | 1,060 | $36K |
| Timolol Maleate Generic | 1,369 | 3,158 | 446 | $15K |
| Dorzolamide Hcl Generic | 1,311 | 2,707 | 420 | $26K |
| Brimonidine Tartrate Generic | 1,038 | 2,285 | 365 | $17K |
| Prednisolone Acetate Generic | 474 | 625 | 344 | $23K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 449 | 894 | 133 | $7,854 |
| Rhopressa Netarsudil Mesylate | 437 | 693 | 126 | $214K |
| Lumigan Bimatoprost | 280 | 614 | 86 | $154K |
| Travoprost Generic | 158 | 353 | 49 | $30K |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | 146 | 279 | 53 | $22K |
| Brinzolamide Generic | 92 | 167 | 43 | $16K |
| Polymyxin B Sul-Trimethoprim Polymyxin B Sulf/Trimethoprim | 90 | 112 | 85 | $764 |
| Combigan Brimonidine Tartrate/Timolol | 85 | 136 | 19 | $28K |
| Vyzulta Latanoprostene Bunod | 72 | 126 | 23 | $35K |
| Atropine Sulfate Generic | 59 | 99 | 32 | $2,356 |
Brand drugs: 3,225 claims; generic drugs: 6,355 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zuhair M Shihab $1,313 ($1,313 in general payments such as food, travel and fees) from 10 companies. The largest payer was Alcon Vision LLC with $431.
| Company | Payments | Amount |
|---|---|---|
| Alcon Vision LLC ALC | 15 | $431 |
| Abbvie Inc. ABBV | 12 | $155 |
| Amgen Inc. AMGN | 4 | $146 |
| Ocular Therapeutix, Inc. OCUL | 7 | $139 |
| Astellas Pharma US Inc 4503.T | 1 | $121 |
| Glaukos Corporation GKOS | 2 | $115 |
| Bausch & Lomb Americas Inc. BLCO | 3 | $67.65 |
| Genentech USA, Inc. ROG.SW | 3 | $66.66 |
| New World Medical,Inc. | 1 | $55.74 |
| Sight Sciences, Inc. SGHT | 1 | $15.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.